Adaptation in clinical development plans and adaptive clinical trial designs
暂无分享,去创建一个
[1] Peter Bauer,et al. A sequential elimination procedure for choosing the best population(s) based on multiple testing , 1989 .
[2] C. Stein. A Two-Sample Test for a Linear Hypothesis Whose Power is Independent of the Variance , 1945 .
[3] Jay Bartroff,et al. Efficient adaptive designs with mid‐course sample size adjustment in clinical trials , 2008, Statistics in medicine.
[4] Draft Guidance. Adaptive Design Clinical Trials for Drugs and Biologics , 2010 .
[5] Sue-Jane Wang,et al. Modification of Sample Size in Group Sequential Clinical Trials , 1999, Biometrics.
[6] Stephen Senn,et al. Examples of option values in drug development , 2003 .
[7] J. Wittes,et al. The role of internal pilot studies in increasing the efficiency of clinical trials. , 1990, Statistics in medicine.
[8] L D Fisher,et al. Self-designing clinical trials. , 1998, Statistics in medicine.
[9] T. L. Lai Andherbertrobbins. Asymptotically Efficient Adaptive Allocation Rules , 1985 .
[10] P. Bauer,et al. Adaptive Two Stage Designs and the Conditional Error Function , 1999 .
[11] P. Bauer,et al. Evaluation of experiments with adaptive interim analyses. , 1994, Biometrics.
[12] Jing Ning,et al. Using short‐term response information to facilitate adaptive randomization for survival clinical trials , 2009, Statistics in medicine.
[13] W. Hoeffding. Lower Bounds for the Expected Sample Size and the Average Risk of a Sequential Procedure , 1960 .
[14] Frank Bretz,et al. Confirmatory Seamless Phase II/III Clinical Trials with Hypotheses Selection at Interim: General Concepts , 2006, Biometrical journal. Biometrische Zeitschrift.
[15] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[16] Peter F Thall,et al. Seamlessly Expanding a Randomized Phase II Trial to Phase III , 2002, Biometrics.
[17] Sue-Jane Wang,et al. Some Controversial Multiple Testing Problems in Regulatory Applications , 2009, Journal of biopharmaceutical statistics.
[18] Jay Bartroff,et al. Generalized Likelihood Ratio Statistics and Uncertainty Adjustments in Efficient Adaptive Design of Clinical Trials , 2008, 1105.4667.
[19] Christopher Jennison,et al. Mid‐course sample size modification in clinical trials based on the observed treatment effect , 2002, Statistics in medicine.
[20] S. Peter Ouyang,et al. A Group Sequential Procedure for Interim Treatment Selection , 2011 .
[21] P. Armitage,et al. Repeated Significance Tests on Accumulating Data , 1969 .
[22] A. Tsiatis,et al. On the inefficiency of the adaptive design for monitoring clinical trials , 2003 .
[23] A Whitehead,et al. Mid-trial design reviews for sequential clinical trials. , 2001, Statistics in medicine.
[24] W. Lehmacher,et al. Adaptive Sample Size Calculations in Group Sequential Trials , 1999, Biometrics.
[25] Andrew J Vickers,et al. Setting the Bar in Phase II Trials: The Use of Historical Data for Determining “Go/No Go” Decision for Definitive Phase III Testing , 2007, Clinical Cancer Research.
[26] K. K. Lan,et al. Interim treatment selection using the normal approximation approach in clinical trials , 2008, Statistics in medicine.
[27] M A Proschan,et al. Designed extension of studies based on conditional power. , 1995, Biometrics.
[28] L Fisher,et al. Statistical Inference for Self‐Designing Clinical Trials with a One‐Sided Hypothesis , 1999, Biometrics.
[29] W. Shih. Sample size re‐estimation – journey for a decade , 2001, Statistics in medicine.
[30] Tze Leung Lai,et al. Power, sample size and adaptation considerations in the design of group sequential clinical trials , 2003 .
[31] Larry Rubinstein,et al. Randomized Phase II Designs , 2009, Clinical Cancer Research.
[32] M Kieser,et al. Combining different phases in the development of medical treatments within a single trial. , 1999, Statistics in medicine.
[33] Steven A. Julious,et al. Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan , 2005 .
[34] Tze Leung Lai,et al. Sequential design of phase II–III cancer trials , 2012, Statistics in medicine.
[35] Bradley P. Carlin,et al. Bayesian Adaptive Methods for Clinical Trials , 2010 .